# IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA

> **NCT02451748** · PHASE4 · COMPLETED · sponsor: **University of Illinois at Chicago** · enrollment: 32 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **OTHER:** Lab Work
- **DRUG:** Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg)
- **DRUG:** Certolizumab pegol (CDP870, tradename Cimzia)
- **DRUG:** Hydroxychloroquine
- **DRUG:** Sulfasalazine
- **DRUG:** Medrol
- **DRUG:** Prednisone
- **DRUG:** Triamcinolone
- **DRUG:** Naproxen
- **DRUG:** Leflunomide
- **DRUG:** Methotrexate
- **DRUG:** humira

## Key facts

- **NCT ID:** NCT02451748
- **Lead sponsor:** University of Illinois at Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08
- **Primary completion:** 2017-09
- **Final completion:** 2017-12
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2024-07-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02451748

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02451748, "IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02451748. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*